 |
|
Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched
analysis within the Korean multicentric registry
Jun Young Lee, Sung Hwa Kim, Yeon Ho Park, Jae Berm Park, Su Hyung Lee, Jaeseok Yang, Myoung Soo Kim, Deok Gie Kim,
Kidney Res Clin Pract. 2022;41(5):623-634. Published online 2022 Jul 21 DOI: https://doi.org/10.23876/j.krcp.21.310
|
|
Citations to this article as recorded by
 Evaluating the efficacy of basiliximab versus no induction in low-immunological-risk kidney transplant recipients: a propensity score matched analysis
Dahao Zhang, Jiqiu Wen, Jianhui Dong, Rong Ma, Shijian Li, Jihua Wu, Ning Wen, Zhiying Lei, Haibin Li, Jun Yin, Xuyong Sun
Renal Failure.2025;[Epub] CrossRef Current use of antithymoglobulin as induction regimen in kidney transplantation: A review
Byung Hwa Park, Ye Na Kim, Ho Sik Shin, Yeonsoon Jung, Hark Rim
Medicine.2024; 103(9): e37242. CrossRef Kidney transplantation in the elderly
Byung Hwa Park, Song Yi Kil, Ye Na Kim, Ho Sik Shin, Yeonsoon Jung, Hark Rim
The Korean Journal of Internal Medicine.2024; 39(6): 875. CrossRef Adverse Drug Events after Kidney Transplantation
Lionel Rostaing, Thomas Jouve, Florian Terrec, Paolo Malvezzi, Johan Noble
Journal of Personalized Medicine.2023; 13(12): 1706. CrossRef
|